Implementation science to understand and design stakeholder informed innovative interventions to improve adolescent and youth HIV prevention and care continuums in rural and urban uganda

Active Cooperative Agreement Awarded Last action

Award ID
UG1HD113241
Recipient
Awarding agency
Obligated
$2,209,142

Award facts

Completion date 63% complete
Place of performance
Uganda

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Adolescents and young adults (AYA) have a high HIV incidence and poor outcomes along the entire HIV prevention and care cascades compared to adults. Despite the high HIV burden, both uptake of oral prep (HIV negatives) and achieving viral suppression (HIV positives) are sub-optimal among youth in sub-saharan africa. Among youth in uganda, uptake and persistence on oral prep is low, with reasons for discontinuation including: pill burden, low perceived severity of HIV, need for partner or parental approval, HIV- related stigma, fear of side-effects and health facility barriers. Cabotegravir, a is new long-acting antiretroviral (CAB-LA) and highly efficacious prep choice that can mitigate barriers to use of daily oral prep. We propose to evaluate evidence-based HIV prevention and care interventions to improve implementation outcomes among high-risk AYA (15-24 years) in uganda. The study covers the continuum of care, will use novel screening methods for HIV risk, will involve teams that are highly experienced in youth-focused clinical trials and implementation science (IMS), will implement MOH approved community differentiated service delivery models for delivery CAB-LA, will evaluate the implementation of the search-youth (SY), a multi-component intervention comprising of life-stage based assessment and support to increase viral suppression in high-risk AYA with HIV, and will use hybrid effectiveness implementation designs to assess these evidence-based interventions. Our aims include: aim 1: using the consolidated framework for implementation research (cfir), we will identify determinants of potential implementation success of two innovations: CAB-LA and SY implementation at the community, clinic, provider, and patient levels in 5 geographically distinct sites in uganda. Aim 2A: using a hybrid effectiveness implementation type II design, we will assess the uptake and persistence of CAB-LA. We will conduct a randomized prospective study to assess effectiveness for the provision of CAB- LA among high risk AYA. Effectiveness outcome will be proportion of study subjects who have initiated CAB-LA and persisted at 18 months of follow-up comparing facility and community delivery options. Implementation outcomes will be feasibility, acceptability, adoption and maintenance using RE-aim. Aim 2B: using a hybrid effectiveness implementation type III design we will assess implementation (feasibility, adoption, fidelity, and sustainment) and effectiveness of the SY intervention in increasing long-term virologic suppression (

Transactions

Action Obligated Date
Amendment $216,390
Amendment $231,483
Amendment $66,666
Amendment $172,619
Amendment $200,464
Amendment $224,769
Amendment -$224,769
Amendment -$172,619
Amendment -$200,464
Amendment $224,769
Amendment $172,619
Amendment $200,464
Amendment $50,000
Amendment $896,751
Amendment $0
Amendment $0
Amendment $50,000
Original award $50,000
Show all 18

Quick answers

Who received award UG1HD113241?

UG1HD113241 was awarded to Mu-Jhu Care LTD by National Institute of Child Health and Human Development (National Institutes of Health) on September 8, 2023.

How much is award UG1HD113241 worth?

$2,209,142 has been obligated on UG1HD113241.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login